Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.

Orhan Kemal YucelRima M SalibaGabriella RondonSairah AhmedAmin AlousiQaiser BashirStefan O CiureaUday PopatIsa KhouriDavid MarinKaty RezvaniPartow KebriaeiElizabeth J ShpallRichard E ChamplinBetül Oran

Published in: Cancer (2017)

Our results confirm that allo-HSCT can provide long-term survival in older MDS patients. Cytogenetics and HCT-CI identify prognostic risk groups and guide selection of older MDS patients who are candidates for allo-HSCT. Cancer 2017;123:2661-70. © 2017 American Cancer Society.

Keyphrases

stem cell transplantation
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
high dose
bone marrow
squamous cell carcinoma
metabolic syndrome
cell proliferation
skeletal muscle
middle aged
papillary thyroid
squamous cell